To the Editor In their Teachable Moment in a recent issue of JAMA Internal Medicine,¹ Drs Akturk and Nippoldt send the important message that the patient, rather than the testosterone level, should be the indication for exogenous testosterone therapy. That message deserves expansion. Although age-adjusted testosterone levels are not routinely used clinically, it should be acknowledged that total testosterone levels fall at about 1.6% per year and free bioavaliable testosterone levels decease by 2.0% to 3.0% per yer.² Therefore, a serum testosterone level of 220 ng/dL in a 45-year-old patient may carry different implications than the same level in a 75-year-old patient. The clinical interpretation is made more cumbersome because of the recognized overlap of symptoms between hypogonadism and normal aging. Age-related testosterone levels have the potential to make testosterone prescribing in elderly patients more judicious and to prevent oversubscribing by reacting to the 鈥渘umber鈥� without context.